CORMEDIX INC. Amortization of Intangible Assets
CORMEDIX INC. (CRMD) reported Amortization of Intangible Assets of $13.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-03-05
- CORMEDIX INC. amortization of intangible assets for the quarter ending 2025-12-31 was $10.14M, a 19360.22% increase year-over-year.
- CORMEDIX INC. amortization of intangible assets for the quarter ending 2025-09-30 was $3.60M, a 6830.01% increase year-over-year.
- CORMEDIX INC. amortization of intangible assets for the quarter ending 2025-06-30 was $51.95K.
- CORMEDIX INC. amortization of intangible assets for the quarter ending 2025-03-31 was $51.95K.
- CORMEDIX INC. amortization of intangible assets for fiscal 2025 was $13.87M, a 8792.31% increase from fiscal 2024.
- CORMEDIX INC. amortization of intangible assets for fiscal 2024 was $156.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $10.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $13.74M derived: sum of 2 quarters · filed 2026-03-05 | $13.79M derived: sum of 3 quarters · filed 2026-03-05 | $13.87M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $3.60M 10-Q · filed 2025-11-12 | $3.65M derived: sum of 2 quarters · filed 2025-11-12 | $3.73M 10-Q · filed 2025-11-12 | $3.76M derived: sum of 4 quarters · filed 2026-03-05 | |
| 2025-06-30 | $51.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $103.90K 10-Q · filed 2025-08-07 | $156.00K derived: sum of 3 quarters · filed 2026-03-05 | $207.95K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2025-03-31 | $51.95K 10-Q · filed 2025-05-06 | $104.05K derived: sum of 2 quarters · filed 2026-03-05 | $156.00K derived: sum of 3 quarters · filed 2026-03-05 | ||
| 2024-12-31 | $52.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $104.05K derived: sum of 2 quarters · filed 2026-03-05 | $156.00K 10-K · filed 2026-03-05 | $155.84K 10-K · filed 2025-03-25 | |
| 2024-09-30 | $51.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $103.90K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $51.95K 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |